Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Assets: 2019-2025

Historic Assets for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $522.5 million.

  • Nurix Therapeutics' Assets rose 1.73% to $522.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $522.5 million, marking a year-over-year increase of 1.73%. This contributed to the annual value of $669.3 million for FY2024, which is 88.23% up from last year.
  • As of Q3 2025, Nurix Therapeutics' Assets stood at $522.5 million, which was down 11.68% from $591.6 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Assets ranged from a high of $669.3 million in Q4 2024 and a low of $308.2 million during Q3 2023.
  • For the 3-year period, Nurix Therapeutics' Assets averaged around $465.5 million, with its median value being $511.0 million (2024).
  • As far as peak fluctuations go, Nurix Therapeutics' Assets plummeted by 32.90% in 2023, and later surged by 96.70% in 2025.
  • Nurix Therapeutics' Assets (Quarterly) stood at $476.8 million in 2021, then dropped by 12.59% to $416.8 million in 2022, then decreased by 14.68% to $355.6 million in 2023, then spiked by 88.23% to $669.3 million in 2024, then increased by 1.73% to $522.5 million in 2025.
  • Its last three reported values are $522.5 million in Q3 2025, $591.6 million for Q2 2025, and $615.0 million during Q1 2025.